#Ozempic #Mounjaro #GLP1 #Tirzepatide #WeightLossDoctor
Should you split your weekly Ozempic, Wegovy, Mounjaro, or Zepbound shot into two smaller doses? Lots of you have asked me about this in the comments. People split their dose to ease the nausea in the first few days and keep food noise down late in the week. In this video, I explain what the pharmacokinetics predict, what the clinical trials did and didn’t test, and the hidden risks most people never hear about.
As an obesity medicine physician, I walk you through half-life, steady state, peak and trough levels, and a simple model of what splitting does to your drug levels. Then I cover the safer, approved ways your doctor can smooth out your week instead.
📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter
🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com
⚠️ This video is for education only and is not personal medical advice. Don’t change your dose, your schedule or your device without talking to the clinician who prescribes it.
TIMESTAMPS
0:00 Should you split your weekly GLP-1 dose?
1:17 Why people split their dose: the peak and the trough
2:56 Half-life and steady state
3:27 What splitting does to your drug levels
5:11 Side effects: the peak or the dose increase?
6:09 What the clinical trials actually tested
7:52 Plausible vs. proven
8:21 Hidden risks: pens and vials
9:16 Compounded vials and dosing errors
10:44 Strategy 1: Slow the titration
11:23 Strategy 2: Find your lowest effective dose
11:56 Strategy 3: Eat around injection day
12:35 Strategy 4: Timing and short-term support
12:58 Strategy 5: Change the molecule
13:45 The verdict
14:14 3 questions for your doctor
REFERENCES
Wegovy (semaglutide) US Prescribing Information, Novo Nordisk. https://www.novo-pi.com/wegovy.pdf
Zepbound (tirzepatide) US Prescribing Information, Eli Lilly. https://medlibrary.org/lib/rx/meds/zepbound/page/5/
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg. Diabetes Obes Metab. 2022;24:94-105.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
Aronne LJ, et al. Tirzepatide vs. semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.
O’Neil PM, et al. Semaglutide vs. liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.
Frias JP, et al. Tirzepatide dose-escalation regimens. Diabetes Obes Metab. 2020;22:938-946.
Huang KP, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632:585-593.
Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370-7380.
Cengiz A, et al. Alternative dosing regimens of GLP-1 receptor agonists. Diabetes Obes Metab. 2025;27:2251-2258.
Ji L, et al. GZR18 once-weekly or bi-weekly dosing: phase 1b/2a trial. Cell Rep Med. 2026;7:102743.
FDA. Dosing errors associated with compounded injectable semaglutide (July 2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
ISMP. Errors possible when microdosing (counting clicks) to dose weight loss medicines (2025). https://www.consumermedsafety.org/safety-articles/errors-possible-when-microdosing-counting-clicks-to-dose-weight-loss-medicines
Lilly Medical: Zepbound single-dose vial and KwikPen guidance. https://medical.lilly.com
America’s Poison Centers semaglutide call data, as reported by CNN/ABC7 (Dec 2023). https://abc7ny.com/fda-poison-control-centers-weight-loss-drug-diabetes/14178159/
Foundayo (orforglipron) US Prescribing Information, Eli Lilly.
Ryan H, et al. OxyContin’s 12-hour problem. Los Angeles Times. 2016.
Modeled peak and trough figures come from a simple one-compartment model built on label half-lives. They are illustrative estimates, not blood levels measured in a trial.
⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
